ECSP034688A - DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS - Google Patents

DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS

Info

Publication number
ECSP034688A
ECSP034688A EC2003004688A ECSP034688A ECSP034688A EC SP034688 A ECSP034688 A EC SP034688A EC 2003004688 A EC2003004688 A EC 2003004688A EC SP034688 A ECSP034688 A EC SP034688A EC SP034688 A ECSP034688 A EC SP034688A
Authority
EC
Ecuador
Prior art keywords
xantina
medications
employment
derivatives
preparation
Prior art date
Application number
EC2003004688A
Other languages
Spanish (es)
Inventor
Frank Himmelsbach
Elke Langkopf
Matthias Eckhardt
Michael Mark
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP034688A publication Critical patent/ECSP034688A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El invento se refiere a xantinas sustituidas de la fórmula general En la que R1 y R4 están definidos como en la reivindicación 1, sus tautómeros, sus esteroisómeros, sus mezclas, sus pro fármacos y sus sales, que se presentan valiosas propiedades farmacológicas, en particular un efecto inhibidor de la actividad de la enzima dipeptidilpeptidasa-1V (DDP-IV).The invention relates to substituted xanthines of the general formula wherein R1 and R4 are defined as in claim 1, their tautomers, their stereoisomers, their mixtures, their pro drugs and their salts, which present valuable pharmacological properties, in particular an inhibitory effect of the activity of the enzyme dipeptidylpeptidase-1V (DDP-IV).

EC2003004688A 2001-02-24 2003-07-14 DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS ECSP034688A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2001109021 DE10109021A1 (en) 2001-02-24 2001-02-24 Xanthine derivatives, their production and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
ECSP034688A true ECSP034688A (en) 2003-08-29

Family

ID=7675407

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004688A ECSP034688A (en) 2001-02-24 2003-07-14 DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS

Country Status (3)

Country Link
DE (1) DE10109021A1 (en)
EC (1) ECSP034688A (en)
ZA (1) ZA200305498B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
DE10251927A1 (en) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (en) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (en) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (en) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (en) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazoles and triazoles, their preparation and use as medicines
DE102004043944A1 (en) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as pharmaceuticals
DE102004044221A1 (en) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (en) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Salt forms of organic compound.
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
KR101927068B1 (en) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013006526A2 (en) * 2011-07-05 2013-01-10 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
JP2019517542A (en) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of linagliptin and metformin

Also Published As

Publication number Publication date
DE10109021A1 (en) 2002-09-05
ZA200305498B (en) 2004-05-07

Similar Documents

Publication Publication Date Title
ECSP034688A (en) DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
UY27181A1 (en) DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS.
UY28103A1 (en) NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
UY28069A1 (en) NEW DERIVATIVES OF XANTINA, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT
UY28749A1 (en) "8- (3-AMINO-PIPERIDIN-1IL) -XANTINAS, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT
ATE323093T1 (en) NEW XANTHINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
ATE388952T1 (en) IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
ATE417046T1 (en) 8-Ä3-AMINO-PIPERIDINE-1-YLÜ-XANTHINE, THEIR PRODUCTION AND THEIR USE AS A MEDICINAL PRODUCT
CY1109928T1 (en) 8- [3-AMINO-Piperidin-1-MATERIAL] -XANTHINES, PRODUCTION OF THESE AND USE AS MEDICINES
UY27427A1 (en) NEW DIHYDRO-PTERIDINONES, PROCEDURES FOR ITS PREPARATION AND ITS USE AS MEDICATIONS
WO2004046148A8 (en) Novel xanthin derivatives, production and use thereof as medicaments
BR0308979A (en) Indolylmaleimide Derivatives
BR0017030A (en) Thiazolylamide Derivatives
BR0108990A (en) Process for preparing antifungal activity pyrimidone derivatives
UY26133A1 (en) SUBSTITUTED DERIVATIVE OF PYRAZOLE.
BR0312863A (en) Polyethylene glycol aldehyde derivatives
MXPA03011682A (en) Substituted n-acyl aniline derivatives, production and use thereof as medicaments.
MX9302459A (en) IMINO CYCLE DERIVATIVES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURES FOR THEIR PREPARATION.
BR0115139A (en) Bisheterocyclic compounds with antitumor and chemosensitizing activity
UY26298A1 (en) "BENCIMIDAZOLE DERIVATIVES SUBSTITUTED WITH AMINO CARBONYL, PROCEDURES FOR ITS PREPARATION AND USE AS MEDICINES."
UY27202A1 (en) AMIDAS OF CARBOXYLIC ACIDS ANTITROMBÓTICAS, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
UY28795A1 (en) NEW 5-ACILINDOLINONES WITH CONTENT IN CYCLALQUIL, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT
UY27628A1 (en) "2'-HALO -3 ', 5'-DIALCOXI-FEN-1'IL-2-IMIDAZOLIDINS AND ITS USE AS A DRUG"
TR200103398T2 (en) Substituted phenylcyclohexanecarboxamides and their use as inhibitors of adenosine intake
UY28143A1 (en) NEW REPLACED NITROGEN HETEROBICICLES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT